United KingdomGOV.UK
Life sciences portfolio support requires a £250m investment commitment
Eligibility guidance requires investment over three years and at least one project starting within 12 months, alongside audited accounts, financial transparency and protection for public funds.
By Taxxa AI OyPublished 21 August 2026
Industry: Scientific research and development · Manufacture of basic pharmaceutical products and pharmaceutical preparations
Companies seeking support through the Life Sciences Large Investment Portfolio must commit to at least £250 million of investment over three years in UK life sciences manufacturing or research and developmentGOV
GOV. At least one eligible project must start within the next 12 months
GOV, according to the government's eligibility guidance.
The scheme, launched on 14 April 2026, is intended to attract high-value investment portfolios to the UK. It may help businesses developing a portfolio of manufacturing or R&D projects access government support and explore funding opportunities. The guidance presents an eligibility route, rather than a promise that a qualifying company will receive a grant.
Applicants must be UK-registered companies or UK-registered establishments.GOV For UK-registered establishments, the guidance additionally requires at least one UK-registered company within the group structure, wholly private-sector status, operations in medicines, MedTech or diagnostics, and all necessary regulatory approvals.
The financial requirements matter for advisers assembling an application. Companies must have three years of audited financial statements for the member company or parent entityGOV. The financial-standing section also calls for commitments, including securities from a parent company, which may be the ultimate parent, UK parent or holding parent, and acceptable protection of public funds for any grants awarded under the scheme.
Financial and corporate information must be readily verifiable through audited accounts and other publicly available disclosures. The government says companies with publicly listed parent entities, or equivalent reporting obligations, may be particularly well placed for a streamlined and proportionate due diligence process. Companies must also demonstrate a record of successfully developing or manufacturing medicines or medical devices in the UK or internationally.
Businesses that believe they qualify can contact LSLIP@officeforlifesciences.gov.uk to find out more. For standalone investments or portfolios below £250 million, the guidance points to other potential capital support: the Life Sciences Innovative Manufacturing Fund for manufacturing projects over £8 million, and the Life Sciences Transformational R&D Investment Fund pilot for R&D projects exceeding £100 million.
The scheme criteria are set out in the Department for Science, Innovation and Technology's Life Sciences Large Investment Portfolio guidance under the government's Life Sciences Sector Plan.
Check the portfolio’s investment timetable, registration and financial evidence against the eligibility criteria before contacting the Office for Life Sciences about support.